Up-front single-session radiosurgery for large brain metastases-volumetric responses and outcomes

BackgroundPatients presenting with large brain metastases (LBM) pose a management challenge to the multidisciplinary neuro-oncologic team. Treatment options include surgery, whole-brain or large-field radiation therapy (WBRT), stereotactic radiosurgery (SRS), or a combination of these.ObjectiveTo determine if corticosteroid therapy followed by SRS allows for efficient minimally invasive care in patients with LBMs not compromised by mass effect.MethodsWe analyzed the change in tumor volume to determine the efficacy of single-session SRS in the treatment of LBM in comparison to other treatment modalities. Twenty-nine patients with systemic cancer and brain metastasis (>= 2.7 cm in greatest diameter) who underwent single-session SRS were included.ResultsAmong 29 patients, 69% of patients had either lung, melanoma, or breast cancer. The median initial tumor size (maximal diameter) was 32 mm (range 28-43), and the median initial tumor volume was 9.56 cm(3) (range 1.56-25.31). The median margin dose was 16 Gy (range 12-18). The average percent decrease in tumor volume compared to pre-SRS volume was 55% on imaging at 1-2 months, 58% at 3-5 months, 64% at 6-8 months, and 57% at > 8 months. There were no adverse events immediately following SRS. Median corticosteroid use after SRS was 21 days. Median survival after radiosurgery was 15 months.ConclusionInitial high-dose corticosteroid therapy followed by prompt single-stage SRS is a safe and efficacious method to manage patients with LBMs (defined as >= 2.7 cm).

Automated summary

This study investigates the efficacy of corticosteroid therapy followed by stereotactic radiosurgery (SRS) in managing patients with large brain metastases (LBM) not compromised by mass effect. The results show that this treatment approach is safe and efficient in reducing tumor volume and improving patient outcomes.